Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients

Harnessing Tumor Mutations for Truly Individualized Cancer Vaccines

(2019) Mathias Vormehr et al.   Annual Review of Medicine

A Multi-Element Expression Score Is A Prognostic Factor In Glioblastoma Multiforme

(2019) Jun-Qi Li et al.   Cancer Management and Research

Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients

(2018) M E Rodríguez-Ruiz et al.   ANNALS OF ONCOLOGY

Methods for improving the immunogenicity and efficacy of cancer vaccines

(2018) Lorenzo Pilla et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Dendritic Cell–Based Cancer Vaccines

(2018) Patricia M. Santos et al.   JOURNAL OF IMMUNOLOGY

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

(2018) Linda M. Liau et al.   Journal of Translational Medicine

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

(2018) Daniel E. Johnson et al.   Nature Reviews Clinical Oncology

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer

(2018) Janos L. Tanyi et al.   Science Translational Medicine

The Clinicopathological and Prognostic Significance of IDO1 Expression in Human Solid Tumors: Evidence from a Systematic Review and Meta-Analysis

(2018) Cheng-Peng Yu et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Actively personalized vaccination trial for newly diagnosed glioblastoma

(2018) Norbert Hilf et al.   NATURE

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

(2018) Derin B. Keskin et al.   NATURE

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

(2017) Ugur Sahin et al.   NATURE

An immunogenic personal neoantigen vaccine for patients with melanoma

(2017) Patrick A. Ott et al.   NATURE

Neoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?

(2017) Thomas C. Wirth et al.   Frontiers in Immunology

Lessons learned from cancer vaccine trials and target antigen choice

(2016) Lisa H. Butterfield   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma

(2016) Sofie Wilgenhof et al.   JOURNAL OF CLINICAL ONCOLOGY

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

(2015) Duane A. Mitchell et al.   NATURE

A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells

(2015) B. M. Carreno et al.   SCIENCE

Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant

(2014) S. Adams et al.   JOURNAL OF IMMUNOLOGY

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

(2012) Steffen Walter et al.   NATURE MEDICINE

Phase I Study Utilizing a Novel Antigen-Presenting Cell-Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer Patients

(2011) M. A. Morse et al.   CLINICAL CANCER RESEARCH

Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial

(2011) Soyoung Baek et al.   Journal of Translational Medicine

Induction of CD8+ T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma

(2010) Hideho Okada et al.   JOURNAL OF CLINICAL ONCOLOGY

Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation

(2009) Leisha A. Emens et al.   JOURNAL OF CLINICAL ONCOLOGY